Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

R-ISS (Multiple Myeloma)

The Revised International Staging System (R-ISS) combines the original ISS (Albumin, Beta-2 Microglobulin) with chromosomal abnormalities (CA) and lactate dehydrogenase (LDH) to better stratify prognosis in newly diagnosed multiple myeloma.

Evidence-based context for fast calculator use

Purpose:
R-ISS stages newly diagnosed multiple myeloma using albumin, beta-2 microglobulin, LDH, and cytogenetics to stratify 5-year survival prognosis.
Population:
patients with the specific hematologic diagnosis and disease phase described by the model
Factors:
Beta-2 Microglobulin, Albumin, LDH Level, Chromosomal Abnormalitiesby iFISH
Reference:
Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869.
HomeR-ISS (Multiple Myeloma)
Pin your most used calculators here by clicking the star in the dropdown.

R-ISS (Multiple Myeloma)

Clinical Context & Background

The Revised International Staging System (R-ISS) combines the original ISS (Albumin, Beta-2 Microglobulin) with chromosomal abnormalities (CA) and lactate dehydrogenase (LDH) to better stratify prognosis in newly diagnosed multiple myeloma. Note: The newer R2-ISS (2022) further incorporates 1q gain/amplification.
Primary Source EvidencePalumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-2869.
Formula Logic
Combines ISS Stage + LDH + CA Genetics (del17p, t(4;14), t(14;16))

Reference Data

R-ISS StageCriteria5-Year OS
Stage IISS I + Normal LDH + Standard Risk CA82%
Stage IINeither Stage I nor Stage III62%
Stage IIIISS III + (High LDH or High Risk CA)40%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use R-ISS (Multiple Myeloma) when r-ISS stages newly diagnosed multiple myeloma using albumin, beta-2 microglobulin, LDH, and cytogenetics to stratify 5-year survival prognosis.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Stage I through Stage III.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm morphology, molecular/cytogenetic data, treatment timing, laboratory units, and the current disease-specific guideline before acting.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Hematology scores are diagnosis-, phase-, and treatment-specific and should not be transferred between diseases.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific hematologic diagnosis and disease phase described by the model

How to apply this result

For a representative case, verify Beta-2 Microglobulin, Albumin, LDH Level, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Hematology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

NCCN-IPI (Lymphoma)CLL-IPIMIPI (Mantle Cell Lymphoma)

Frequently Asked Questions

When should R-ISS (Multiple Myeloma) be used?

Use it for patients with the specific hematologic diagnosis and disease phase described by the model when all required inputs and the intended clinical setting are confirmed.

Can R-ISS (Multiple Myeloma) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.